Clinical Trials Logo
  1. Home
  2. Influenza B
  3. NCT06254820

Dose, Safety, and Pathogenicity of a New Influenza B Strain

Influenza B Clinical Trial

Official title:
An Exploratory Study To Establish The Dose, Safety, And Pathogenicity Of A New Influenza B Challenge Strain In Healthy Participants 18 To 55 Years Of Age

Clinical Trial Summary

This is an exploratory study of an influenza B challenge strain to determine the optimum infectious titer of challenge agent in healthy participants 18 to 55 years of age.

Clinical Trial Description

This is an exploratory study of an influenza B challenge strain to determine the optimum safe infectious titer of challenge agent in healthy participants 18 to 55 years of age. A total of up to 80 participants may be given influenza B challenge virus. The study will be conducted in 2 parts. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3). Each participant will remain in the study for approximately 1 month from admission to quarantine to the last clinic visit. The study is divided into three phases: 1. Screening phase: Screening will occur between Day -90 to Day -2/-1. has been signed by the participant. 2. Quarantine phase: Participants will stay in the quarantine unit for approximately 11 days (from Day -2/-1 to Day 8). One or two days prior to the day of inoculation with the challenge virus, participants will be admitted to quarantine where their eligibility will be reassessed. If participants remain eligible for the study, they will receive the challenge virus on Day 0. Participants will undergo a range of clinical assessments and safety monitoring for the entirety of their stay in quarantine. Participants will be discharged from the quarantine unit on Day 8 (or may remain longer at the principal investigator's discretion). 3. Outpatient phase: Final follow-up visit 28 days (±3 days) after the day they receive the virus. Their symptoms will be reassessed, and a complete safety examination performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06254820
Study type Interventional
Source Hvivo
Contact Alex Mann
Phone +44(0)207 756 1300
Email projectadmin@hvivo.com
Status Recruiting
Phase Phase 2
Start date October 3, 2023
Completion date February 8, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02487173 - Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B N/A
Recruiting NCT06191393 - SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings N/A
Completed NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel N/A
Not yet recruiting NCT05787444 - Clinical Validation of the LumiraDx SARS-CoV-2 & Flu A/B Test in Detecting and Differentiating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Influenza A (Flu A), and/or Influenza B (Flu B)
Completed NCT02767414 - Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B N/A
Recruiting NCT06207929 - Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship Between Passively-collected Data From Wearable Activity Devices and Respiratory Viral Infections
Completed NCT02287467 - Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza Phase 3
Completed NCT02067286 - Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer N/A
Suspended NCT05728970 - Performance Evaluation of the LumiraDX SARS-CoV-2 Ag Ultra and LumiraDX SARS-CoV-2 & Flu A/B Tests at Point of Care (POC) Sites
Completed NCT01302418 - Collection and Testing of Respiratory Samples N/A
Completed NCT05732610 - MGC Health COVID-19 & Flu A+B Home Multi Test Usability Study N/A
Enrolling by invitation NCT06229444 - Predict + Protect Study: Exploring the Effectiveness of a Predictive Health Education Intervention on the Adoption of Protective Behaviors Related to ILI N/A
Completed NCT01052480 - Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza Phase 2
Recruiting NCT06175611 - Clinical Performance Study for EDAN's COVID-19/Flu A/Flu B/RSV Test Kits on Subjects Suspected of Respiratory Infection
Terminated NCT04810949 - Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml N/A